(AEs) were recorded for 7 and 30 days post each dose, respectively. Serious AEs (SAEs), HZ cases and potential immune-mediated diseases (pIMDs) were recorded throughout the study.
Pharmacist Prescribing and Care in Patients with
Background. Pharmacists have the authorization to prescribe medications for the treatment of uncomplicated urinary tract infections (UTI) in some Canadian provinces. However, there is limited data on the outcomes of this care by pharmacists. Our objective was to evaluate the effectiveness, safety, and patient satisfaction with pharmacist prescribing and care in patients with uncomplicated UTI.
Methods. We conducted a prospective registry trial in 39 community pharmacies in the Canadian province of New Brunswick. Adult patients were enrolled if they presented to the pharmacy with either symptoms of UTI with no current antibacterial treatment (Pharmacist-Initial Arm) or if they presented with a prescription for an antibacterial to treat UTI from another healthcare provider (Physician-Initial Arm).
Pharmacists assessed patients and if they had complicating factors or red flags for systemic illness or pyelonephritis, they were excluded from the study. Pharmacists either prescribed antibacterial therapy, modified antibacterial therapy, provided education only, or referred to physician, as appropriate. The primary outcome was clinical cure at 2 weeks and the secondary outcomes included adverse events and patient satisfaction.
Results. A total of 748 patients were enrolled (87% in the Pharmacist-Initial Arm), average age was 40.8 (SD 15.9) years. Clinical cure was achieved in 89% of patients. Of those that did not have sustained symptom resolution, most (6% overall) had symptom recurrence after completion of therapy. Adverse events were reported by 7% of patients and 88% of those continued their medication. Most adverse events were gastrointestinal-related and transient. The patient satisfaction survey reflected very high levels of satisfaction for the care they received, as well as for trust and accessibility of the pharmacist.
Conclusion. Pharmacist management of uncomplicated UTI is effective, safe, and patient satisfaction is very high.
Disclosures. All authors: No reported disclosures. Saturday, October 6, 2018: 12:30 PM Background. JNJ-8678 is a RSV-specific fusion inhibitor and a potential new treatment for respiratory infections caused by RSV. Data from a Phase 1b study of PK, safety and antiviral effects in hospitalized RSV-infected infants are presented.
Antiviral Effects, Pharmacokinetics (PK), and Safety of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678 (JNJ-8678), in RSV-infected Infants
Methods. 37 and 7 patients, respectively, were randomized to JNJ-8678 (ascending doses, Table) or placebo (PBO) treatment once daily for 7 days. PK assessments were based on sparse sampling using a population PK model in adults scaled for pediatrics, accounting for allometric principles and maturation of drug clearance pathways. Safety was evaluated by AE reporting, lab and ECG assessments. Antiviral activity was assessed by measuring viral load (VL) using a quantitative RT-PCR assay for RSV RNA from nasal swabs.
Results. Sparse PK data are described by an integrated PK model (table) and indicated PK parameters for different dose levels were similar across age groups. Treatment
